Facteurs pronostiques du cancer bronchique non à petites cellules localement avancé et métastatique
Mots-clés :
Cancers bronchiques non à petites cellules ; pronostic, survieRésumé
Ré
Téléchargements
Références
Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104:569-77.
Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier A. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 2008;44:115-22.
Statistiques sanitaires mondiales 2012. Bibliothèque OMS 2012.
Ben Abdallah, M., Zehani, S., & Hizem Ben Ayoub, W. (2009). Registre des Cancers Nord-Tunisie. Ministre de la Sante Publique Institut Salah Azaiez Institut National de la Sante Publique, Tunis, Tunisia.
Dautzenberg B, Choukroun G. Cancers bronchopulmonaires primitifs non à petites cellules et tumeurs à malignité réduite. Encycl Méd Chir ( Elsevier Masson, Paris), Pneumologie 1998 :1-16.
Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier A et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007;43:149-60.
De Carol P, Benfield J. Lung cancer in young persons. J Thorac Cardiovasc Surg 1982;83:372—6.
Sugio K, Ishida T, Kaneko S, et al. Surgically resected lung cancer in young adults. Ann Thorac Surg 1992;53:127-31.
Dujon C, Azarian R, Petitpretz P. Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d'une série rétrospective. Rev Mal Respir 2009;26:952-60.
Chermiti Ben Abdallah F, Ben Ali G, Sadok Boudaya M, Milka M, Chtourou A, Taktak S et al. Traitement et pronostic du cancer bronchique non à petites cellules au stade avancé. Rev Mal Respir 2014;31:214-20.
Moro D, Nagy-Mignotte H, Bolla M, Colonna M, Brichon PY, Brambilla C, Schaerer R, Vrousos C : Evaluation de la survie et des facteurs pronostiques de 2000 cancers broncho-pulmonaires enregistrés en 10 ans dans une unité multidisciplinaire de cancérologie. Bull Cancer 1997;84:155-61.
Paesmans M : Les facteurs pronostiques. Rev Mal Respir 2008;25:3S99-106.
Finkelstein DM, Ettinger DS, Ruckdeschel JC : Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-9.
Wataya H, Okamoto T, Maruyama R, et al. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer 2009;64:341-5.
Grivaux M, Zureik M, Marsal L, et al. Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2009;26:37-44.
D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:116-9.
Widikker G, Rochat T, Simonet M. Non small cell lung cancer and thoracic surgery: the role of the primary care physician. Rev Médicale Suisse 2008;4:2208-11. 18. Moro-Sibilot D, Pluquet E, Zalcman G, et al. Quel traitement pour un patient de PS 2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ? Rev Mal Respir 2007;24:120-4.
Mornex F, Martin E, Belliére A, Milleron B, Van Houtte P, Chapet O. Cancer bronchique non à petites cellules localement évolué: place de la chimiothérapie exclusive. Cancer Radiother. 2002;6:117-24.
Patel S, Sanborn R, Thomas CJ. Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease. Thorac Surg Clin 2008;18:393-401.
Furuse K, Fukuoka M, Kawahara M. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
Chargari C, Deutsch E, Le Péchoux C. États des lieux desassociations chimioradiothérapeutiques et place potentielledes thérapies ciblées dans les cancers non à petites cellules 2009;13:114-22.
Christensen E, Harvald T, Jendresen M. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997;12:880-4.
Kashiwabara K, Koshi S, Itonaga K. Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. Lung Cancer 2002;35:237-41.
Yorio J, Xie Y, Yan J, Gerber D. Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 2009;4:1322-30.
Quarterman R, McMillan A, Ratcliffe M. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;125:108-13.
Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 2001;34:243-52.
Aragoneses F, Moreno N, Leon P. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002;36:59-63.
Salomaa E, Sällinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-8.
Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M : 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;8: 1-8.
